Test Overview
Fluorescence In Situ Hybridization (FISH)
This test detects rearrangements involving the ERG gene region (21q22) via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded tissue specimens. FISH is performed using a dual-color break-apart probe (Empire Genomics) to qualitatively assess for the presence of ERG rearrangements that are associated with a subset of prostatic adenocarcinoma. Testing for ERG gene rearrangement may aid in: 1. Diagnosis and classification of a subset of prostatic adenocarcinoma 2. Diagnosis and classification of a subset of neuroendocrine prostate cancer 3. Confirmation of presence or absence of ERG gene rearrangement in prostatic adenocarcinoma cases with equivocal ERG immunohistochemical expression. 4. Differential diagnosis of poorly differentiated prostate cancer versus poorly differentiated urothelial cancer 5. Diagnosis of ERG positive metastatic prostatic adenocarcinoma 6. Diagnosis of ERG positive prostatic adenocarcinoma with low or equivocal ERG immunohistochemical expression (for example, treated prostate cancer).
Interpretive report provided.
This test detects rearrangements involving ERG, however it will not identify the translocation partner.
Test Details
- CGERG
- ERG gene region 21q22
- FFPE FISH for ERG
- Prostatic Adenocarcinoma
- Prostate Cancer
- ERG FISH
Specimen Requirements
Submit a formalin-fixed, paraffin block of the tumor tissue (with matched benign prostate tissue if available); store at room temperature.
Additional Information
By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws. Test includes pathologist interpretation of results billed as a separate additional charge. This test is not available without interpretation.